Cancer Treatment Reviews
Volume 30, Issue 5 , Pages 461-472 , August 2004

Histone deacetylase inhibitors – a new tool to treat cancer

  • Raz Somech

      Affiliations

    • Laboratory of Molecular Hemato-Oncology, Sheba Cancer Research Center, Chaim Sheba Medical Center, Tel-Hashomer, Sackler School of Medicine, Tel-Aviv University, Israel
    • Dana Children's Hospital, Tel Aviv Sourasky Medical Center, Sackler School of Medicine, Tel-Aviv University, Israel
    • Corresponding Author InformationCorresponding author. Tel.: +972-3-5302397; fax: +972-3-5302377
    • ,
  • Shai Izraeli

      Affiliations

    • Laboratory of Molecular Hemato-Oncology, Sheba Cancer Research Center, Chaim Sheba Medical Center, Tel-Hashomer, Sackler School of Medicine, Tel-Aviv University, Israel
    • ,
  • Amos J Simon

      Affiliations

    • Laboratory of Molecular Hemato-Oncology, Sheba Cancer Research Center, Chaim Sheba Medical Center, Tel-Hashomer, Sackler School of Medicine, Tel-Aviv University, Israel

References 

  1. Liu MC, Gelmann EP. P53 gene mutations: case study of a clinical marker for solid tumors. Semin. Oncol. 2002;29:246–257
  2. Kornberg RD, Lorch Y. Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell. 1999;98:285–294
  3. Vermaak D, Ahmad K, Henikoff S. Maintenance of chromatin states: an open-and-shut case. Curr. Opin. Cell Biol. 2003;15:266–274
  4. Marks PA, Richon VM, Breslow R, Rifkind RA. Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol. 2001;13:477–483
  5. Neumeister P, Albanese C, Balent B, Greally J, Pestell RG. Senescence and epigenetic dysregulation in cancer. Int. J. Biochem. Cell Biol. 2002;34:1475–1490
  6. Thiagalingam S, Cheng KH, Lee HJ, Mineva N, Thiagalingam A, Ponte JF. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann. N. Y. Acad. Sci. 2003;983:84–100
  7. Jenuwein T, Allis CD. Translating the histone code. Science. 2001;293:1074–1080
  8. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer. 2001;1:194–202
  9. Wang C, Fu M, Mani S, Wadler S, Senderowicz AM, Pestell RG. Histone acetylation and the cell-cycle in cancer. Front. Biosci. 2001;6:D610–D629
  10. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. 2000;92:1210–1216
  11. Burke LJ, Baniahmad A. Co-repressors 2000. FASEB J. 2000;14:1876–1888
  12. Allfrey VG, Faulkner R, Mirsky AE. Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc. Natl. Acad. Sci. USA. 1964;51:786–794
  13. Brownell JE, Allis CD. An activity gel assay detects a single, catalytically active histone acetyltransferase subunit in Tetrahymena macronuclei. Proc. Natl. Acad. Sci. USA. 1995;92:6364–6368
  14. Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 2003;370:737–749
  15. Bernstein BE, Tong JK, Schreiber SL. Genomewide studies of histone deacetylase function in yeast. Proc. Natl. Acad. Sci. USA. 2000;97:13708–13713
  16. Bjerling P, Silverstein RA, Thon G, Caudy A, Grewal S, Ekwall K. Functional divergence between histone deacetylases in fission yeast by distinct cellular localization and in vivo specificity. Mol. Cell. Biol. 2002;22:2170–2181
  17. Gao L, Cueto MA, Asselbergs F, Atadja P. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J. Biol. Chem. 2002;277:25748–25755
  18. Ito A, Kawaguchi Y, Lai CH, et al.  MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J. 2002;21:6236–6245
  19. Magnaghi-Jaulin L, Groisman R, Naguibneva I, et al.  Retinoblastoma protein represses transcription by recruiting a histone deacetylase. Nature. 1998;391:601–605
  20. Nicolas E, Ait-Si-Ali S, Trouche D. The histone deacetylase HDAC3 targets RbAp48 to the retinoblastoma protein. Nucleic Acids Res. 2001;29:3131–3136
  21. Chen Lf, Fischle W, Verdin E, Greene WC. Duration of nuclear NF-kappa B action regulated by reversible acetylation. Science. 2001;293:1653–1657
  22. Ozawa Y, Towatari M, Tsuzuki S, et al.  Histone deacetylase 3 associates with and represses the transcription factor GATA-2. Blood. 2001;98:2116–2123
  23. Wang L, Hiebert SW. TEL contacts multiple co-repressors and specifically associates with histone deacetylase-3. Oncogene. 2001;20:3716–3725
  24. Hang Y, Li N, Caron C, et al.  HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J. 2003;22:1168–1179
  25. Huang Y, Myers SJ, Dingledine R. Transcriptional repression by REST: recruitment of Sin3A and histone deacetylase to neuronal genes. Nat. Neurosci. 1999;2:867–872
  26. Koizume S, Tachibana K, Shiraishi M. Treatment of tumor cells with histone deacetylase inhibitors results in altered recruitment of methyl-CpG binding proteins to a methylated CpG island. Biol. Chem. 2003;384:787–790
  27. Iizuka M, Smith MM. Functional consequences of histone modifications. Curr. Opin. Genet. Dev. 2003;13:154–160
  28. Lachner M, Jenuwein T. The many faces of histone lysine methylation. Curr. Opin. Cell. Biol. 2002;14:286–298
  29. Santos-Rosa H, Schneider R, Bannister AJ, et al.  Active genes are tri-methylated at K4 of histone H3. Nature. 2002;419:407–411
  30. Clayton AL, Mahadevan LC. MAP kinase-mediated phosphoacetylation of histone H3 and inducible gene regulation. FEBS Lett. 2003;546:51–58
  31. Yamamoto Y, Verma UN, Prajapati S, Kwak YT, Gaynor RB. Histone H3 phosphorylation by IKK-alpha is critical for cytokine-induced gene expression. Nature. 2003;423:655–659
  32. Galasinski SC, Resing KA, Goodrich JA, Ahn NG. Phosphatase inhibition leads to histone deacetylases 1 and 2 phosphorylation and disruption of corepressor interactions. J. Biol. Chem. 2002;277:19618–19626
  33. Stuurman N, Heins S, Aebi U. Nuclear lamins: their structure, assembly, and interactions. J. Struct. Biol. 1998;122:42–66
  34. Goldman RD, Gruenbaum Y, Moir RD, Shumaker DK, Spann TP. Nuclear lamins: building blocks of nuclear architecture. Genes Dev. 2002;16:533–547
  35. Holaska JM, Wilson KL, Mansharamani M. The nuclear envelope, lamins and nuclear assembly. Curr. Opin. Cell Biol. 2002;14(3):357–364
  36. Gruenbaum Y, Wilson KL, Harel A, Goldberg M, Cohen M. Review: nuclear lamins-structural proteins with fundamental functions. J. Struct. Biol. 2000;129:313–323
  37. Jenkins H, Whitfield WG, Goldberg MW, Allen TD, Hutchison CJ. Evidence for the direct involvement of lamins in the assembly of a replication competent nucleus. Acta Biochim. Pol. 1995;42:133–143
  38. Moir RD, Spann TP, Herrmann H, Goldman RD. Disruption of nuclear lamin organization blocks the elongation phase of DNA replication. J. Cell Biol. 2000;149:1179–1192
  39. Spann TP, Goldman AE, Wang C, Huang S, Goldman RD. Alteration of nuclear lamin organization inhibits RNA polymerase II-dependent transcription. J. Cell Biol. 2002;156(4):603–608
  40. Nili E, Cojocaru GS, Kalma Y, et al.  Nuclear membrane protein LAP2beta mediates transcriptional repression alone and together with its binding partner GCL (germ-cell-less). J. Cell Sci. 2001;114(Pt 18):3297–3307
  41. Gerasimova TI, Byrd K, Corces VG. A chromatin insulator determines the nuclear localization of DNA. Mol. Cell. 2000;6:1025–1035
  42. Kosak ST, Skok JA, Medina KL, et al.  Subnuclear compartmentalization of immunoglobulin loci during lymphocyte development. Science. 2002;296:158–162
  43. Imai S, Nishibayashi S, Takao K, et al.  Dissociation of Oct-1 from the nuclear peripheral structure induces the cellular aging-associated collagenase gene expression. Mol. Biol. Cell. 1997;8:2407–2419
  44. Ozaki T, Saijo M, Murakami K, Enomoto H, Taya Y, Sakiyama S. Complex formation between lamin A and the retinoblastoma gene product: identification of the domain on lamin A required for its interaction. Oncogene. 1994;9:2649–2653
  45. Jagatheesan G, Thanumalayan S, Muralikrishna B, et al.  Colocalization of intranuclear lamin foci with RNA splicing factors. J. Cell Sci. 1999;112:4651–4661
  46. Schirmer EC, Florens L, Guan T, Yates JR, Gerace L. Nuclear membrane proteins with potential disease links found by subtractive proteomics. Science. 2003;301(5638):1380–1382
  47. Polioudaki H, Kourmouli N, Drosou V, et al.  Histones H3/H4 form a tight complex with the inner nuclear membrane protein LBR and heterochromatin protein 1. EMBO Rep. 2001;2(10):920–925
  48. Mahlknecht U, Hoelzer D. Histone acetylation modifiers in the pathogenesis of malignant disease. Mol. Med. 2000;6:623–644
  49. Gayther SA, Batley SJ, Linger L, et al.  Mutations truncating the EP300 acetylase in human cancers. Nat. Genet. 2000;24:300–303
  50. Bryan EJ, Jokubaitis VJ, Chamberlain NL, et al.  Mutation analysis of EP300 in colon, breast and ovarian carcinomas. Int. J. Cancer. 2002;102:137–141
  51. Coupry I, Roudaut C, Stef M, et al.  Molecular analysis of the CBP gene in 60 patients with Rubinstein–Taybi syndrome. J. Med. Genet. 2002;39:415–421
  52. Amann JM, Nip J, Strom DK, et al.  ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol. Cell. Biol. 2001;21:6470–6483
  53. Borrow J, Stanton VP, et al.  The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat. Genet. 1996;14:33–41
  54. Rowley JD, Reshmi S, Sobulo O, et al.  All patients with the T(11;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders. Blood. 1997;90:535–541
  55. Minucci S, Nervi C, Lo Coco F, Pelicci PG. Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias?. Oncogene. 2001;20:3110–3115
  56. Wu WS, Vallian S, Seto E, Yang WM, Edmondson D, Roth S, et al.  The growth suppressor PML represses transcription by functionally and physically interacting with histone deacetylases. Mol. Cell. Biol. 2001;21:2259–2268
  57. David G, Alland L, Hong SH, Wong CW, DePinho RA, Dejean A. Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein. Oncogene. 1998;16:2549–2556
  58. Dhordain P, Lin RJ, Quief S, et al.  The LAZ3 (BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression. Nucleic Acids Res. 1998;26:4645–4651
  59. Lin RJ, Nagy L, Inoue S, Shao W, Miller WH, Evans RM. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature. 1998;391:811–814
  60. Hagemann RF, Evans TC. Influence of dimethyl sulphoxide on glycine transport in sarcoma 180 tumour cells. Nature. 1968;218:583–584
  61. Candido EP, Reeves R, Davie JR. Sodium butyrate inhibits histone deacetylation in cultured cells. Cell. 1978;14:105–113
  62. Yoshida M, Nomura S, Beppu T. Effects of trichostatins on differentiation of murine erythroleukemia cells. Cancer Res. 1987;47:3688–3691
  63. Vigushin DM, Ali S, Pace PE, Mirsaidi N, Ito K, Adcock I, et al.  Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin. Cancer Res. 2001;7:971–976
  64. Rahman MM, Kukita A, Kukita T, Shobuike T, Nakamura T, Kohashi O. Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages. Blood. 2003;101:3451–3459
  65. Butler LM, Agus DB, Scher HI, et al.  Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 2000;60:5165–5170
  66. Coffey DC, Kutko MC, Glick RD, et al.  Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro. Med. Pediatr. Oncol. 2000;35:577–581
  67. Lee SC, Bottaro A, Insel RA. Activation of terminal B cell differentiation by inhibition of histone deacetylation. Mol. Immunol. 2003;39:923–932
  68. Kim MS, Kwon HJ, Lee YM, et al.  Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat. Med. 2001;7:437–443
  69. Chambers AE, Banerjee S, Chaplin T, et al.  Histone acetylation-mediated regulation of genes in leukaemic cells. Eur. J. Cancer. 2003;39:1165–1175
  70. Ju R, Muller MT. Histone deacetylase inhibitors activate p21(WAF1) expression via ATM. Cancer Res. 2003;63:2891–2897
  71. Saito A, Yamashita T, Mariko Y, et al.  A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci. USA. 1999;96:4592–4597
  72. Catley L, Weisberg E, Tai YT, et al.  NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003;102:2615–2622
  73. Gore SD, Carducci MA. Modifying histones to tame cancer:clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors. Expert. Opin. Investig. Drugs. 2000;9:2923–2934
  74. Gilbert J, Baker SD, Bowling MK, et al.  A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin. Cancer Res. 2001;7:2292–2300
  75. Carducci MA, Gilbert J, Bowling MK, et al.  A phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin. Cancer Res. 2001;7:3047–3055
  76. Gore SD, Weng LJ, Zhai S, et al.  Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin. Cancer Res. 2001;7:2330–2339
  77. Gore SD, Weng LJ, Figg WD, et al.  Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin. Cancer Res. 2002;8:963–970
  78. Ferrara FF, Fazi F, Bianchini A, et al.  Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res. 2001;61:2–7
  79. Warrell RP, He LZ, Richon V, Calleja E, Pandolfi PP. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J. Natl. Cancer Inst. 1998;90:1621–1625
  80. Zhou DC, Kim SH, Ding W, Schultz C, Warrell RP, Gallagher RE. Frequent mutations in the ligand-binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo. Blood. 2002;99:1356–1363
  81. Marshall JL, Rizvi N, Kauh J, et al.  A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J. Exp. Ther. Oncol. 2002;2:325–332
  82. Sandor V, Bakke S, Robey RW, et al.  Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin. Cancer Res. 2002;8:718–728
  83. Piekarz RL, Robey R, Sandor V, et al.  Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood. 2001;98:2865–2868
  84. Nemunaitis JJ, Orr D, Eager R, et al.  Phase I study of oral CI-994 in combination with gemcitabine in treatment of patients with advanced cancer. Cancer J. 2003;9:58–66
  85. Prakash S, Foster BJ, Meyer M, et al.  Chronic oral administration of CI-994: a phase 1 study. Invest. New Drugs. 2001;19:1–11
  86. Fournel M, Trachy-Bourget MC, Yan PT, et al.  Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors. Cancer Res. 2002;62:4325–4330
  87. Gottlicher M, Minucci S, Zhu P, et al.  Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001;20:6969–6978
  88. Kramer OH, Zhu P, Ostendorff HP, et al.  The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J. 2003;22:3411–3420
  89. Blaheta RA, Cinatl J. Anti-tumor mechanisms of valproate: a novel role for an old drug. Med. Res. Rev. 2002;22:492–511
  90. Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target. Cancer Cell. 2003;4:13–18

PII: S0305-7372(04)00078-7

doi: 10.1016/j.ctrv.2004.04.006

Cancer Treatment Reviews
Volume 30, Issue 5 , Pages 461-472 , August 2004

Article Tools

* Image Usage & Resolution